Objectives: Hepatic ischemia-reperfusion is a major clinical problem with limited treatment options. The pathophysiology of hepatic ischemia-reperfusion is characterized by mitochondrial dysfunction and cellular energy deficits. Sirtuin 1 is an energy-sensing enzyme known to modulate mitochondrial biogenesis. We hypothesized that pharmacologic activation of sirtuin 1 is protective after hepatic ischemia-reperfusion injury. Design: Animal study. Setting: University-based experimental laboratory. Subjects: Wild-type C57BL/6 mice. Interventions: C57BL/6 mice were subjected to 60-minute partial hepatic ischemia-reperfusion and posttreated with sirtuin 1 activator, SRT1720 (20 mg/kg), or vehicle. Blood and liver were collected at 24 hours after ischemia-reperfusion for analyses of hepatic injury, adenosine triphosphate levels, mitochondrial mass, autophagy, inflammation, and oxidative stress. H4IIE hepatoma cells and rat primary hepatocytes were incubated with oxyrase to induce hypoxia followed by reoxygenation in the presence or absence of SRT1720 for assessment of mitochondrial mass, mitochondrial membrane potential, and autophagy. Measurements and Main Results: SRT1720 restored the reduction in mitochondrial mass, enhanced autophagy, and preserved ade-nosine triphosphate levels in the liver after ischemia-reperfusion, which was associated with a decrease in ischemia-reperfusioninduced hepatic injury, apoptosis, and necrosis. Ischemia-reperfusion-induced inflammation was also significantly reduced by SRT1720 as measured by systemic and hepatic cytokine and chemokine levels, as well as a decrease in neutrophil infiltration to the liver. Furthermore, oxidative stress was markedly attenuated in the SRT1720-treated mice compared with the vehicle. SRT1720 treatment increased adenosine triphosphate levels and survival of cultured hepatocytes after hypoxia-reoxygenation. SRT1720 not only increased the mitochondrial mass but also increased mitochondrial membrane potential per cell in cultured hepatocytes after hypoxia-reoxygenation. Moreover, SRT1720 prevented the hypoxia-reoxygenation-induced mitochondrial depolarization and resulted in an enhancement of autophagy in cultured hepatocytes after hypoxia-reoxygenation. Conclusions: Pharmacologic stimulation of sirtuin 1 attenuates liver injury after hepatic ischemia-reperfusion by restoring mitochondrial mass and membrane potential, which is associated with the enhancement of autophagy. (Crit Care Med 2016; 44:e651-e663) CONCLUSIONS Posttreatment with SRT1720 is protective in the setting of hepatic I/R. This effect is associated with the restoration of cellular energy status, as well as the recovery of mtMS and mtMP, and an enhancement of autophagy in hepatocytes.
H epatic ischemia-reperfusion (I/R) injury most commonly occurs after oncologic liver resection, transplantation, and circulatory shock (1) . Specifically, I/R injury has been associated with delayed graft function and biliary complications after liver transplantation (2, 3) . The pathophysiology of I/R is characterized by energy depletion, sterile inflammation, and oxidative injury, leading to cell death (4) . Despite our increased understanding of the mechanisms behind hepatic I/R injury, the clinical management remains limited to preventive and supportive care (5) .
Mitochondria are the major organelles responsible for adenosine triphosphate (ATP) generation in the cell. They work by pumping protons through the respiratory chain into the intermembrane space to form the mitochondrial membrane potential (mtMP) (6) . The mtMP drives ATP generation, and its disruption, also known as mitochondrial depolarization, halts ATP synthesis (6) . Therefore, mtMP can be used as a reliable measure of mitochondrial activity (6, 7) . In I/R injury, the ischemic phase is characterized by ATP depletion because of a switch to anaerobic respiration. Reperfusion is usually accompanied by the disruption of mitochondrial function, which in turn hampers the cellular attempt at regaining the energy and metabolic homeostasis for cell survival (8, 9) . Given the underlying mitochondrial dysfunction in I/R-induced injury, we sought to investigate a therapeutic strategy aimed at preserving or restoring mitochondrial integrity to protect organs against I/R injury.
The autophagy salvage pathway is an additional means of energy generation in cells and can be activated by various cellular stressors, including hypoxia and nutrient starvation (10) . Autophagy is a process of degradation and recycling of large molecules and dysfunctional organelles. In this process, targeted cellular cargoes are engulfed by an autophagic vesicle derived from the cell membrane (10) . The vesicle is then acidified via lysosomal fusion, which initiates the enzymatic degradation of its cargo (11) . In this context, autophagy demonstrates protective effects in various settings of nutrient scarcity and energy depletion (12, 13) .
Sirtuins are a family of seven highly conserved mammalian proteins involved in cellular energy homeostasis (14) . Among them, sirtuin 1 (Sirt1) is a wellcharacterized energy-sensing enzyme, which responds to stress, starvation, and caloric restriction (15) . Sirt1 localizes to both the nucleus and cytoplasm, and its deacetylase activity is dependent on nicotinamide adenine dinucleotide (14) . Activation of Sirt1 promotes the transcription of genes in the regulation of mitochondrial biogenesis to maintain energy and metabolic homeostasis (16, 17) . Thus, modulation of Sirt1 activity in various disease conditions has been gaining traction, and multiple studies have shown its beneficial effects in protecting various organs from I/Rinduced injury (18) (19) (20) (21) (22) . In this study, we hypothesized that pharmacologic activation of Sirt1 would restore I/R-induced mitochondrial dysfunction and enhance autophagy, thereby attenuating hepatic I/R injury. To test our hypothesis, we first used an established mouse model of partial hepatic ischemia (23, 24) . Animals subjected to ischemia were posttreated with SRT1720, a small molecule allosteric stimulator of Sirt1 (25) . The effects of SRT1720 on the liver after I/R were analyzed using various injury, metabolic, and inflammatory variables. In addition, a cell culture model of hypoxia-reoxygenation (H/R) injury was also employed . SRT1720 restores cellular energy status after hepatic ischemia-reperfusion (I/R). Ischemic liver tissues of the vehicle-and SRT1720-treated mice were collected at 24 hr after reperfusion. Relative expression of the mitochondrial proteins: succinate dehydrogenase subunit B (SDHB) (A); cytochrome oxidase IV (COXIV) (B), as well as the autophagy markers; microtubule associate protein 1 light chain 3 (LC3) (C); and sequesterome 1 (SQSTM1) (D) were measured in the liver by Western blot. E, Adenosine triphosphate (ATP) levels in the liver lysates were measured. Data are presented as mean ± se (n = 6-8 per group). *p < 0.05 versus control; #p < 0.05 versus vehicle.
to validate the effects of SRT1720 on mitochondrial mass (mtMS), mtMP, and autophagy at the cellular level in hepatocytes. . SRT1720 attenuates hepatic injury after ischemia-reperfusion (I/R). Ischemic liver tissues and blood of the vehicle-and SRT1720-treated mice were collected at 24 hr after reperfusion. Serum levels of hepatic injury markers: aspartate aminotransferase (AST) (A), alanine aminotransferase (ALT) (B), and lactate dehydrogenase (LDH) (C) were measured. D, Representative photomicrographs of histologic staining with hematoxylin and eosin of liver tissues at ×100 magnification. E, Extent of liver injury was graded using the Suzuki score by a blinded investigator as described in the Supplementary Methods (Supplemental Digital Content 1, http://links.lww.com/CCM/B655). F, Representative photomicrographs of terminal deoxynucleotidyl transferase dUTP nick-end labeling (green) and 4′,6-diamidino-2-phenylindole as nuclear counterstained (blue) at ×40 magnification. *The selected areas shown in the insets at ×400 magnification. G, Caspase-3 activity was determined in the liver lysates. Data are presented as mean ± se (n = 6-8 per group). *p < 0.05 versus control; #p < 0.05 versus vehicle. oxyrase (Oxyrase, Mansfield, OH) in glucose-free, pyruvatefree Dulbecco modified Eagle medium (DMEM). Oxyrase is an enzyme derived from the cytoplasmic membrane of Eschericia coli, which consumes dissolved oxygen in the media. Reoxygenation was achieved by refreshing with DMEM medium containing 10% heat-inactivated fetal bovine serum, 1% penicillin-streptomycin, and 2 mM glutamine. Cells were treated with 0.1% DMSO or SRT1720 at reoxygenation. Measurements of cell survival, mtMS, mtMP, and assessments of autophagic vesicles are detailed in Supplementary Methods (Supplemental Digital Content 1, http://links.lww.com/CCM/B655).
METHODS

Animal Experiments
Statistical Analysis
All data are expressed as mean ± se and compared by one-way analysis of variance and the Student-Newman-Keuls test. Differences in values were considered significant if the p value is less than 0.05.
RESULTS
SRT1720 Restores Cellular Energy Status After Hepatic I/R
Succinate dehydrogenase subunit B (SDHB) and cytochrome oxidase complex IV (COXIV) are mitochondrial proteins and major components of the respiratory chain, which have been used as markers of mtMS (26) . Both SDHB and COXIV were significantly decreased by 31.8% and 31.9%, respectively, in the livers of the vehicle group compared with the control ( Fig. 1, A and  B) . SRT1720-treated mice had near baseline levels of SDHB and COXIV in the liver, which was 1.4-and 1.7-fold higher than the vehicle group, respectively ( Fig. 1 , A and B).
Light chain (LC)-3II protein is a marker of autophagy, and its expression level has been correlated to the number of autophagic vesicles (27) . We observed a 1.6-fold increase in LC3II expression in the SRT1720-treated mice compared with the vehicle group after I/R (Fig. 1C) . Sequesterome 1 (SQSTM1) is an intracellular protein that is degraded by autophagy (27) . The level of SQSTM1 was significantly decreased by 19.1% in the SRT1720-treated mice compared with the vehicle. (Fig.  1D ). In addition, ATP levels in the liver were decreased by 21% in the vehicle group compared with the control (Fig. 1E) . In contrast, ATP levels in the liver of the SRT1720-treated mice were close to control levels ( Fig. 1E ). However, there were no significant changes in the expression levels of Sirt1 protein among the groups (data not shown). These results suggest that SRT1720 treatment facilitated the recovery of ATP, which was associated with increased mtMS and autophagy in the liver after I/R.
SRT1720 Attenuates Liver Injury After Hepatic I/R
Serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and lactate dehydrogenase (LDH) were used as indicators of hepatic injury; all of which were dramatically increased in the vehicle group after I/R (Fig. 2, A-C) . Treatment with SRT1720 decreased the levels of AST by 81.0%, ALT by 75.1%, and LDH by 82.1% when compared with the vehicle group (Fig. 2 , A-C).
Histologic assessment of the liver on hematoxylin and eosin revealed significant areas of necrosis and congestion extending toward the portal triad in the vehicle group (Fig. 2D) . This was markedly improved with SRT1720 treatment where necrosis was limited to the immediate centrilobular area (Fig. 2D ). The extent of hepatic injury in the vehicle group and the subsequent protection by the treatment are semiquantitatively represented using the Suzuki classification ( Fig. 2E) . A TUNEL assay was conducted to assess for apoptotic cell death after hepatic I/R (28) . The vehicle-treated group had numerous TUNEL-positive nuclei, which were absent in both control and SRT1720-treated mice after I/R (Fig. 2F) . This was further supported by a 51.8% increase in caspase-3 activity in the vehicle group when compared with the control and a decrease to baseline control levels with SRT1720 treatment (Fig. 2G) .
SRT1720 Decreases Inflammation After Hepatic I/R
Liver and serum proinflammatory cytokine levels were measured to assess for local and systemic inflammation after hepatic I/R. Liver interleukin (IL)-6 and IL-1β messenger RNA (mRNA) levels were increased by 9.2-and 6.1-fold compared with the control, respectively (Fig. 3, A and B) . Their levels were significantly decreased by 82.8% and 71.2%, respectively, with SRT1720 treatment when compared with the vehicle (Fig. 3, A  and B ). In addition, liver IL-6 protein levels were significantly increased by 1.3-fold in the vehicle group in comparison to the control, whereas they were markedly reduced by 52.3% in the SRT1720 treatment group (Fig. 3C) . The change of IL-6 protein levels was also observed in the serum, where there was a 40.7-fold increase in IL-6 levels after I/R in the vehicle group compared with the control (Fig. 3D) . Serum IL-6 levels were decreased by 79.5% in the SRT1720-treated group when compared with the vehicle (Fig. 3D ).
SRT1720 Inhibits Neutrophil Infiltration After Hepatic I/R
Neutrophil infiltration is a hallmark of hepatic I/R injury (29) . As expected, liver mRNA levels of the neutrophil chemoattractants, keratinocyte chemoattractant (KC), and macrophage inhibitory protein (MIP)-2 were markedly increased after I/R in the vehicle group compared with the control (Fig. 4, A and B) . SRT1720 treatment significantly decreased the mRNA levels of KC and MIP-2 by 58.6% and 92.4%, respectively, compared with the vehicle group (Fig. 4, A and B) . In addition, myeloperoxidase activity was measured as a marker for neutrophil infiltration and was increased by 10.4-fold in the vehicle group compared with the control, whereas it was reduced to control levels with SRT1720 treatment (Fig. 4C) . The effect of SRT1720 on neutrophil infiltration was further supported by immunohistochemistry against anti-granulocyte receptor 1, a protein marker of neutrophils (Fig. 4D) . The extent of liver neutrophil infiltration in the vehicle-treated mice was in stark contrast to that in the control and SRT1720-treated mice, where neutrophils were rare ( Fig. 4D ).
SRT1720 Reduces Oxidative Stress After Hepatic I/R
Increased oxidative stress is another characteristic of I/R injury (4) . Liver mRNA levels of the oxidative stress mediators, cyclooxygenase (COX)-2 and inducible nitric oxide synthase (iNOS), were markedly increased after I/R in the vehicle group when compared with the control (Fig. 5, A and B) . Their levels were decreased by 96.0% and 84.2%, respectively, in the SRT1720-treated mice when compared with the vehicle (Fig. 5, A and B) . Furthermore, measurement of the levels of 4-hydroxynonenal (4-HNE) adducts, a marker of lipid peroxidation (30) , showed a 27.6% increase in the vehicle group when compared with the control, whereas they were reduced to baseline control levels with SRT1720 treatment (Fig. 5C ).
SRT1720 Increases Survival and ATP Levels of Cultured Hepatocytes After H/R
After demonstrating the effect of SRT1720 on mice undergoing hepatic I/R, we sought to investigate the direct role of SRT1720 on cultured hepatocytes after H/R. Rat H4IIE hepatoma cells were incubated with oxyrase to induce hypoxia, followed by reoxygenation with a fresh medium for 4 hours in the absence or presence of SRT1720. H/R caused a 27.6% and 21.7% decrease in the survival rate of H4IIE cells and ATP levels, respectively, compared with the normoxia control (Fig. 6, A and B) . On the other hand, treatment with SRT1720 improved the survival and ATP levels of H4IIE cells after H/R to 103.6% and 92.7% of the normoxia control, respectively (Fig. 6, A and B) .
SRT1720 Enhances mtMS and mtMP of Cultured Hepatocytes After H/R
To assess the effects of SRT1720 on the mitochondria after H/R, H4IIE cells were stained with mitrotracker green (MTG) and mitrotracker red (MTR) for measurements of mtMS and mtMP, respectively, by flow cytometry. At 4 hours of reoxygenation, the mean fluorescence intensity (MFI) of both MTG and MTR was significantly decreased by 43.7% and 58.8%, respectively, compared with the normoxia control. In contrast, treatment with 100 and 500 nM of SRT1720 to H/R-injured cells increased the MFI of MTG by 1.7-and 3.0-fold (Fig. 7, A and  C) , as well as MTR by 2.0-and 4.2-fold, respectively, compared with the untreated H/R-injured cells (Fig. 7, B and D) .
SRT1720 Enhances Autophagy in Cultured
Hepatocytes After H/R Given the enhancement of autophagy observed in the livers of the SRT1720-treated mice, we next examined whether SRT1720 had a direct effect on autophagy in hepatocytes exposed to H/R. LC3II protein expression in H/R-injured H4IIE cells was slightly decreased compared with the normoxia control; however, with SRT1720 treatment, the LC3II levels were higher than those in both normoxia control and H/R-injured cells, especially at 24 hours of reoxygenation (Fig. 8A) . Furthermore, cells were stained with acridine orange for the detection of autophagic vesicles under a fluorescence microscope (Eclipse Ti-s, Melville, NY). The autophagic vesicles (shown in red) could be detected in several H4IIE cells exposed to H/R, whereas they were more abundant and of higher intensity in the SRT1720-treated cells at 24 hours of reoxygenation ( Fig. 8B) .
SRT1720-Induced Autophagy Is Dependent on the mtMP After H/R
To examine the mtMP in individual cells, the intensity of MTR staining (indicated mtMP) was replotted against MTG staining (indicated mtMS) from the flow cytometric data described in Figure 9 . Under normoxic conditions, healthy H4IIE cells had intact mitochondria, as indicated by 97.9% of the population positioned above the reference line (Fig. 9A) . When H4IIE cells were exposed to H/R, at 4 hours of reoxygenation, 25.2% of the population lay below the reference line, indicating mitochondrial depolarization (Fig. 9, A and C) . On the other hand, treatment with SRT1720 decreased the percentage of cells below the reference line to 8.1% (Fig. 9, A and C) . Cotreatment of SRT1720 with 500 nM of antimycin A, a mitochondrial depolarizing agent (31), increased the percentage of cells with depolarized mitochondria to 14.6% below the reference line (Fig. 9, A and C) .
To establish the relationship between the SRT1720-induced enhancement in autophagy and mtMP, we further quantified the amount of autophagic vesicles in H4IIE cells by flow cytometry with CYTO-ID staining. H4IIE cells exposed to H/R had an increase in CYTO-ID-positive staining to 3.4% of the population in contrast to the normoxia control cells, which were arbitrarily gated at 1% of the population with positive staining for comparison ( Fig. 9,  B and D) . Treatment with SRT1720 increased the population of the CYTO-ID-positive cells to 11.3% (Fig. 9, B and D) . However, addition of antimycin A with SRT1720 reduced the number of the CYTO-IDpositive cells to a level similar to the normoxia control ( Fig. 9,  B and D) . Taken together, these results indicate that the increase in the mtMP stimulated by SRT1720 is needed for the enhancement of autophagy in H/R-injured H4IIE cells.
SRT1720 Increases mtMS, mtMP, and Autophagy in Primary Hepatocytes
After H/R To further verify the conclusion from the study of H4IIE cells, further experiments were performed on primary hepatocytes isolated from rats. The change in mtMS and mtMP was determined in primary hepatocytes exposed to different durations of hypoxia. There was a 32.2% and 45.8% decrease in the MFI of MTG and a 43.9% and 55.2% decrease in the MFI of MTR after exposure to 2 and 3 hours of hypoxia, respectively, followed by 4 hours of reoxygenation, compared with the normoxia control (Fig. 10, A and B) . Two hours of hypoxia was selected for subsequent experiments. Treatment with 250 and 1,000 nM of SRT1720 increased the MFI of MTG by 8.9% and 17.0%, as well as the MFI of MTR by 10.9% and 25.3%, respectively, after 4 hours of reoxygenation (Fig. 10, C and D) . In addition, 10.5% of H/R-injured hepatocytes treated with SRT1720 were positive for CYTO-ID compared with 5.6% in the normoxia control (Fig. 10E) . We then used chloroquine, an inhibitor of the degradation of autophagic vesicles (27) , to examine the effect of SRT1720 on autophagic flux. In the presence of chloroquine, the population of the CYTO-ID-positive cells in the H/Rinjured hepatocytes with SRT1720 treatment was increased to 15.6% (Fig. 10E ). This effect was inhibited by antimycin A. Similar to H4IIE cells, SRT1720 treatment increased the mtMS and mtMP, which was again associated with the enhancement of autophagy in primary hepatocytes exposed to H/R.
To examine the effects of SRT1720 on stimulating the mitochondrial biogenesis pathway, we measured the expression of nuclear transcription factor (Nrf)-1 and mitochondrial transcription factor A (mtTFA), two well-know downstream mediators of the Sirt1 activation pathway (32, 33) . There was a 37.8% increase in mRNA levels of Nrf-1 in H/R-injured primary hepatocytes treated with 1,000 nM of SRT1720 after 1 hour of reoxygenation compared with normoxia ( Fig. 11A) . Similarly, there was an increase in the protein expression of mtTFA in the SRT1720-treated primary hepatocytes compared with H/R alone after 4 hours of reoxygenation (Fig. 11B) . These results indicate that SRT1720 effectively activated the Sirt1 signaling pathway.
DISCUSSION
Hepatic I/R is primarily a surgical problem with limited clinical interventions available (1). Mitochondrial dysfunction is a central feature of I/R injury because of its importance in energy homeostasis and its direct involvement in mediating oxidative injury and apoptosis (9) . In this study, we show that pharmacologic activation of Sirt1 markedly attenuates hepatic injury, increases mtMS, and enhances autophagy after I/R. In addition, there is a significant reduction in necrosis, apoptosis, inflammation, neutrophil infiltration, and oxidative stress in the livers of mice posttreated with SRT1720 after hepatic I/R. SRT1720 is a potent activator of Sirt1 (25) . To examine its direct effects on mitochondria, we employ a cell culture model using H4IIE cells and rat primary hepatocytes, which Figure 9 . SRT1720-induced autophagy is dependent on mitochondrial membrane potential after hypoxia-reoxygenation (H/R) in H4IIE hepatocytes. H4IIE hepatocytes underwent 6 hr of oxyrase-induced hypoxia in glucose-, pyruvate-, and serum-free media followed by 4 or 18 hr of reoxygenation in complete media. At the beginning of reoxygenation, cells were treated with 0.125% dimethyl sulfoxide (vehicle), 500 nM of SRT1720, or 500 nM of SRT1720 plus 500 nM of antimycin A (AA). A and C, After 4 hr of reoxygenation, cells were stained with mitotracker green (MTG) and mitotracker red (MTR) FM dye for measurement of mitochondrial mass (mtMS) per cell and mitochondrial membrane potential (mtMP) per cell, respectively. Cells below the reference line (thin diagonal line) were considered as cells with depolarized mitochondria. B and D, After 18 hr of reoxygenation, cells were stained with CYTO-ID green fluorescein isothiocyanate (FITC) autophagy dye, arbitrary gate drawn at 1% baseline autophagy rate in the normoxia control cells (vertical thin line). Data are presented as mean ± se (n = 6 per group), representative of three independent experiments. *p < 0.05 versus control; #p < 0.05 versus H/R; †p < 0.05 versus H/R plus 100 nM SRT1720. FSC-A = forward scatter-area. display reductions in mtMS and mtMP after exposure to H/R. We demonstrate dose-dependent enhancement of mtMS and mtMP per cell with SRT1720 treatment in hepatocytes exposed to H/R. We further demonstrate that SRT1720 treatment increases the expression of Nrf-1 and mtTFA in primary hepatocytes exposed to H/R. These two proteins are important transcription factors involved in the regulation of mitochondrial biogenesis and serve as downstream mediators of Sirt1 (32, 33) , indicating that SRT1720 activates the mitochondrial biogenesis pathway in hepatocytes. Consistent with previous studies, we show that stimulation of mitochondrial activity is protective in the setting of I/R (8, 34) . In addition, enhancement of mitochondrial biogenesis by Sirt1 protects cultured renal proximal tubule cells from oxidative injury and protects animals from renal I/R injury (35, 36) . In addition, we show an increase in the percentage of H4IIE cells with depolarized mitochondria after H/R, which is partially reversed by treatment with SRT1720. The importance of this finding is highlighted by the fact that mitochondrial depolarization has been identified as a culprit in both necrotic and apoptotic cell death after I/R (37, 38) .
In addition to its effect on reversing mitochondrial dysfunction, Sirt1 has been shown to directly inhibit p53-mediated apoptosis after renal I/R (18) . In our study, we demonstrate the absence of TUNELpositive nuclei in the livers of SRT1720-treated mice after hepatic I/R. The contribution of apoptotic cell death to ischemic liver injury has gained attention after it was first reported by Sasaki et al (39) . The debate on the predominant mechanism of cell death, whether by necrosis or apoptosis, is complicated by the vast commonalities in the pathways leading to cell death (37) . Nevertheless, it has been shown that inhibition of apoptosis through the blockade of caspase activity is protective in the setting of hepatic I/R (40) . This is consistent with our results, which show that SRT1720 treatment decreases caspase-3 activity to baseline levels in the liver after I/R.
The sterile inflammatory response after I/R injury can be attributed to the release of damage-associated molecular patterns from necrotic and apoptotic cells during the early phase of I/R (29, 41) . Herein we demonstrate a significant attenuation of local and systemic inflammation with SRT1720 treatment, which may be directly related to its cellular protective effects against I/R-induced necrosis and apoptosis. In support of this, our cell culture study clearly indicates a direct prosurvival effect of SRT1720 on hepatocytes exposed to H/R. On the other hand, Sirt1 has been shown to inhibit the nuclear factor-κB (NF-κB) canonical pathway (42) , and therefore, SRT1720 treatment may also directly attenuate the release of proinflammatory cytokines. Neutrophil infiltration is another characteristic feature of the inflammatory response in hepatic I/R (43) . The chemokines KC and MIP-2 have been directly implicated in the process of neutrophil recruitment after hepatic I/R and neutralization of these chemokines are associated with decreased neutrophil infiltration and improved outcomes (43) . We show that treatment with SRT1720 markedly decreases the expression of KC and MIP-2, as well as neutrophil infiltration assessed by myeloperoxidase activity and immunohistochemistry, in the liver after hepatic I/R.
Oxidative stress is another hallmark of I/R injury. Multiple studies have shown partial protection to hepatic I/R using antioxidants (44) , with variable clinical outcomes (45, 46) .
Complicating the picture, oxidative stress and inflammation are highly intertwined. For instance, neutrophils generate reactive oxygen species (ROS) within infiltrated tissue as part of their microbial defense mechanism (47) . In addition, ROS can activate NF-κB and increase the transcription of inflammatory mediators, such as COX-2 and iNOS (48, 49) . Pharmacologic and genetic inhibition of COX-2 has been shown to be protective in the setting of hepatic I/R (50, 51) . iNOS is one of the several enzymes catalyzing nitric oxide release. Nitric oxide contributes to oxidative injury through the generation of peroxynitrite, which induces cell injury through lipid peroxidation. Several studies have demonstrated that iNOS is in fact deleterious in the setting of hepatic I/R (52, 53) . Our results indicate that SRT1720 inhibits COX-2 and iNOS mRNA expression after hepatic I/R, likely contributing to the decrease in oxidative injury as measured by 4-HNE adducts, a marker for lipid peroxidation.
Evidence of the protective effects of autophagy during I/R has been accumulating (54, 55) . Bhogal et al (56) showed that inhibition of autophagy using 3-methyladenine increases apoptosis in primary human hepatocytes under oxidative stress. More recently, work by Yun et al (57) suggest that there is an impaired autophagy response after hepatic I/R, where pharmacologic inhibition of autophagy further exacerbates injury. Likewise, our results implicate autophagy as a protective mechanism of SRT1720 after hepatic I/R, as shown by the increase in LC3II expression and decrease in SQSTM1 protein levels in the liver after I/R. Although we do not observe any change in protein levels of hepatic LC3II after I/R and H4IIE cells after H/R in comparison to their controls, an increase in autophagic vesicles can be detected in the H4IIE cells and primary hepatocytes after H/R by using acridine orange staining and the CYTO-ID autophagy detection kit (Enzo Life Science, Farmingdale, NY). In contrast, treatment with SRT1720 increases LC3II expression significantly in the liver and H4IIE cells. These results suggest that Western blotting for LC3II may not be sensitive enough to detect autophagy after ischemia and hypoxia at the time points used in this study. Further kinetic studies are needed to monitor the changes in LC3II expression in this model.
Using the cell culture model, we further identify a correlation between mtMP and enhancement in autophagy after SRT1720 treatment of hepatocytes exposed to H/R. We detect an increase in mtMS and mtMP, as well as an increase in the number of autophagic vesicles, in the H/R-injured hepatocytes after SRT1720 treatment compared with untreated H/R-injured hepatocytes. However, by disrupting the mtMP with antimycin A, the initial enhancement of autophagy by SRT1720 is significantly diminished. Similar to our observation, the dependence of autophagy on mitochondrial activity has been described in yeast and other mammalian cells (31, 58) . On the other hand, the elimination of dysfunctional mitochondria by autophagy has also been reported in hepatocytes exposed to hypoxia (59) . Our findings suggest a potential pathway linking Sirt1 and its effect on mitochondria to autophagy regulation; the detailed mechanism of which will be the subject of future investigation. Figure 11 . SRT1720 activates the mitochondrial biogenesis pathway in primary hepatocytes after hypoxia-reoxygenation (H/R). Primary hepatocytes underwent oxyrase-induced hypoxia in glucose-and pyruvate-free media followed by reoxygenation in complete media. Cells were lysed, and messenger RNA (mRNA) and protein were used for analysis. Primary hepatocytes were subjected to 2 hr of hypoxia followed by 1 hr (A) or 4 hr (B) of reoxygenation. Cells were treated with 250 nM or 1,000 nM of SRT1720 at reoxygenation. A, mRNA expression of the mitochondrial biogenesis marker nuclear transcription factor (Nrf)-1. B, Protein expression of mitochondrial transcription factor A (mtTFA) were measured by reverse transcriptase-polymerase chain reaction and Western blot, respectively (*p < 0.05 versus normoxia [N]). Data are presented as mean ± se (n = 3 per group), representative of two independent experiments.
